Skip to main content
. Author manuscript; available in PMC: 2014 Apr 29.
Published in final edited form as: Cancer Res. 2011 Oct 31;71(24):7597–7607. doi: 10.1158/0008-5472.CAN-11-1080

Figure 3.

Figure 3

Antiproliferative effects of BMS-754807 and/or hormonal therapy in vitro. MCF-7/AC-1 cells were cultured, and after 6 days, treatment cell proliferation measured as above. Proliferation was assessed in the presence of BMS-754807, hormonal therapies, and a fixed ratio of increasing amount of combinations, as indicated. Cell proliferation is expressed as the percentage of the cells compared with the control wells (1 nmol/L androstenedione-treated cells). A, 4-OH tamoxifen (***, P < 0.001); B, letrozole (***, P < 0.001); C, fulvestrant (****, P < 0.0001). Points, mean; bars, SE. D, CI values at the 50% (Fa50) and 75% (Fa75) fraction affected were plotted for the treatment combinations. All CI values plotted were significantly synergistic (P < 0.001). Columns, mean; bars, SE.

HHS Vulnerability Disclosure